Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis
Inhibitors of the IL-6 signaling pathway, such as tocilizumab, are frequently administered for the treatment of immune diseases, e.g., rheumatoid arthritis and multicentric Castleman’s disease. The aim of this systematic review and meta-analysis was to ascertain the effects of IL-6 pathway inhibitors on weight and body mass index (BMI). Using PRISMA guidelines, we systematically reviewed relevant articles from three databases (PubMed, OVID, EMBASE). A random effects model was used to estimate standardized mean change (SMCC). Ten studies with a total of 1531 patients were included in the meta-analysis for weight and ten studies with a total of 1537 patients were included in the BMI meta-analysis. The most commonly administered IL-6 pathway inhibitor was tocilizumab. IL-6 pathway inhibitors were associated with increases in weight (SMCC = 0.09, <i<p</i< = 0.016, 95% CI [0.03, 0.14]) and BMI (SMCC = 0.10, <i<p</i< = 0.0001, 95% CI [0.05, 0.15]). These findings suggest that the IL-6 pathway is involved in weight regulation. Modulating IL-6 signaling may be a potential future therapeutic avenue used as an adjunct for the treatment of disorders associated with weight changes, such as cancer cachexia and anorexia nervosa..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
International Journal of Molecular Sciences - 21(2020), 17, p 6290 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olivia Patsalos [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BMI |
|---|
| doi: |
10.3390/ijms21176290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ007237863 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ007237863 | ||
| 003 | DE-627 | ||
| 005 | 20240412214613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms21176290 |2 doi | |
| 035 | |a (DE-627)DOAJ007237863 | ||
| 035 | |a (DE-599)DOAJ89b0ab6283664415b301e4758c38fa4c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 050 | 0 | |a QD1-999 | |
| 100 | 0 | |a Olivia Patsalos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Inhibitors of the IL-6 signaling pathway, such as tocilizumab, are frequently administered for the treatment of immune diseases, e.g., rheumatoid arthritis and multicentric Castleman’s disease. The aim of this systematic review and meta-analysis was to ascertain the effects of IL-6 pathway inhibitors on weight and body mass index (BMI). Using PRISMA guidelines, we systematically reviewed relevant articles from three databases (PubMed, OVID, EMBASE). A random effects model was used to estimate standardized mean change (SMCC). Ten studies with a total of 1531 patients were included in the meta-analysis for weight and ten studies with a total of 1537 patients were included in the BMI meta-analysis. The most commonly administered IL-6 pathway inhibitor was tocilizumab. IL-6 pathway inhibitors were associated with increases in weight (SMCC = 0.09, <i<p</i< = 0.016, 95% CI [0.03, 0.14]) and BMI (SMCC = 0.10, <i<p</i< = 0.0001, 95% CI [0.05, 0.15]). These findings suggest that the IL-6 pathway is involved in weight regulation. Modulating IL-6 signaling may be a potential future therapeutic avenue used as an adjunct for the treatment of disorders associated with weight changes, such as cancer cachexia and anorexia nervosa. | ||
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a tocilizumab | |
| 650 | 4 | |a siltuximab | |
| 650 | 4 | |a weight | |
| 650 | 4 | |a BMI | |
| 650 | 4 | |a spondyloarthritis | |
| 653 | 0 | |a Biology (General) | |
| 653 | 0 | |a Chemistry | |
| 700 | 0 | |a Bethan Dalton |e verfasserin |4 aut | |
| 700 | 0 | |a Hubertus Himmerich |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Molecular Sciences |d MDPI AG, 2003 |g 21(2020), 17, p 6290 |w (DE-627)DOAJ00014584X |x 14220067 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:17, p 6290 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms21176290 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/89b0ab6283664415b301e4758c38fa4c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/21/17/6290 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1661-6596 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1422-0067 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 17, p 6290 | ||